Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Mar 21 04:00PM ET
8.40
Dollar change
+0.65
Percentage change
8.39
%
IndexRUT P/E- EPS (ttm)-1.08 Insider Own4.63% Shs Outstand147.77M Perf Week15.38%
Market Cap1.25B Forward P/E- EPS next Y-0.70 Insider Trans-16.39% Shs Float141.70M Perf Month0.84%
Income-159.49M PEG- EPS next Q-0.29 Inst Own92.59% Short Float6.11% Perf Quarter28.83%
Sales178.96M P/S6.97 EPS this Y14.71% Inst Trans0.39% Short Ratio5.25 Perf Half Y82.21%
Book/sh1.37 P/B6.12 EPS next Y24.31% ROA-26.57% Short Interest8.66M Perf Year156.88%
Cash/sh1.50 P/C5.61 EPS next 5Y28.67% ROE-62.41% 52W Range2.28 - 8.95 Perf YTD40.12%
Dividend Est.- P/FCF- EPS past 5Y-1.51% ROI-38.50% 52W High-6.15% Beta1.69
Dividend TTM- Quick Ratio2.81 Sales past 5Y17.92% Gross Margin53.95% 52W Low268.42% ATR (14)0.70
Dividend Ex-Date- Current Ratio2.89 EPS Y/Y TTM30.45% Oper. Margin-86.27% RSI (14)59.49 Volatility9.13% 9.69%
Employees619 Debt/Eq1.10 Sales Y/Y TTM5.10% Profit Margin-89.12% Recom1.25 Target Price9.71
Option/ShortYes / Yes LT Debt/Eq1.04 EPS Q/Q52.38% Payout- Rel Volume1.75 Prev Close7.75
Sales Surprise3.06% EPS Surprise10.26% Sales Q/Q3.66% EarningsFeb 11 AMC Avg Volume1.65M Price8.40
SMA207.82% SMA509.10% SMA20051.95% Trades Volume2,855,227 Change8.39%
Date Action Analyst Rating Change Price Target Change
Mar-21-25Upgrade Goldman Neutral → Buy $9
Jul-05-23Resumed JP Morgan Overweight $15
Jan-05-23Initiated Scotiabank Sector Outperform $15
Dec-21-22Upgrade Piper Sandler Neutral → Overweight $7.50 → $14
Aug-25-22Initiated Credit Suisse Underperform $8
Jun-03-22Initiated Piper Sandler Neutral $7.50
Feb-16-22Reiterated JP Morgan Overweight $75 → $50
Feb-16-22Reiterated Goldman Neutral $54 → $21
Feb-16-22Reiterated BTIG Research Buy $35 → $30
Feb-16-22Reiterated BofA Securities Buy $40 → $32
Mar-20-25 03:06PM
Mar-11-25 08:00AM
Feb-14-25 10:44AM
Feb-12-25 12:00PM
09:56AM
09:40AM Loading…
09:40AM
02:11AM
Feb-11-25 06:30PM
05:35PM
04:45PM
04:05PM
Feb-10-25 07:19AM
Feb-05-25 04:05PM
Feb-04-25 10:28AM
Jan-23-25 05:06PM
06:21AM Loading…
06:21AM
Jan-22-25 04:05PM
Jan-17-25 09:40AM
Jan-16-25 08:33AM
Jan-15-25 10:10AM
Jan-14-25 07:30AM
Jan-07-25 07:30AM
Jan-02-25 04:05PM
Dec-09-24 09:53AM
Dec-07-24 06:30PM
Dec-05-24 07:16AM
Dec-03-24 07:30AM
Nov-29-24 09:40AM
Nov-25-24 01:55PM
Nov-15-24 09:55AM
10:18AM Loading…
Nov-08-24 10:18AM
02:29AM
Nov-07-24 06:30PM
06:15PM
05:11PM
04:05PM
07:30AM
Nov-06-24 07:28AM
Oct-09-24 04:05PM
Oct-04-24 04:35AM
Aug-29-24 07:30AM
Aug-22-24 04:03PM
Aug-01-24 07:00PM
06:20PM
05:23PM
04:05PM
Jul-21-24 06:00AM
Jul-15-24 12:00PM
Jul-11-24 04:05PM
May-31-24 07:30AM
May-29-24 04:05PM
May-25-24 08:30AM
May-24-24 09:58AM
May-23-24 06:00AM
May-16-24 02:30PM
May-08-24 06:43PM
12:19PM
03:54AM
May-07-24 07:30PM
05:47PM
05:40PM
04:37PM
04:05PM
Apr-26-24 10:02AM
Apr-17-24 04:05PM
Apr-02-24 04:05PM
Mar-27-24 04:30PM
08:30AM
Mar-11-24 12:01AM
Feb-22-24 04:05PM
Feb-15-24 10:09AM
06:37AM
Feb-14-24 05:16PM
04:43PM
04:05PM
Feb-13-24 02:23AM
Feb-12-24 09:16AM
Jan-29-24 04:05PM
Dec-27-23 04:05PM
Dec-12-23 05:50AM
Dec-11-23 03:30PM
Dec-09-23 08:30AM
Dec-05-23 07:30AM
Nov-10-23 01:52PM
Nov-09-23 04:17PM
04:05PM
Nov-07-23 07:30AM
Nov-02-23 04:05PM
Oct-26-23 10:02AM
Oct-17-23 07:57AM
Sep-27-23 05:14AM
Sep-13-23 07:30AM
Aug-30-23 04:30PM
Aug-28-23 11:53PM
Aug-24-23 10:29AM
Aug-02-23 05:35PM
04:30PM
04:05PM
Jul-29-23 12:12AM
Jul-19-23 08:52AM
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PISKEL KYLEChief Financial OfficerMar 14 '25Option Exercise6.322,50015,800271,510Mar 17 07:34 PM
GRIFFIN MICHELLE RENEEDirectorMar 13 '25Sale7.1936,291260,93215,394Mar 17 07:33 PM
GRIFFIN MICHELLE RENEEDirectorMar 13 '25Proposed Sale7.1936,291260,861Mar 13 05:28 PM
HERSHBERG ROBERTDirectorMar 12 '25Sale7.5953,000402,27069,690Mar 12 07:48 PM
NEUPERT PETER MDirectorMar 10 '25Option Exercise4.0750,000203,500234,690Mar 12 07:47 PM
NEUPERT PETER MDirectorMar 10 '25Sale7.0510,00070,500224,690Mar 12 07:47 PM
HERSHBERG ROBERTDirectorMar 12 '25Proposed Sale7.5953,000402,270Mar 12 05:30 PM
NEUPERT PETER MDirectorMar 10 '25Proposed Sale7.0510,00070,450Mar 10 02:48 PM
LO FRANCISChief People OfficerMar 05 '25Sale6.9920,875145,845332,846Mar 06 07:22 PM
BOBULSKY SUSANChief Commercial Officer, MRDMar 05 '25Sale6.9826,023181,641347,238Mar 06 07:22 PM
BENZENO SHARONChief Commercial Ofc Imm MedMar 05 '25Sale6.9844,665311,792392,723Mar 06 07:21 PM
PISKEL KYLEChief Financial OfficerMar 05 '25Sale6.9810,32072,072269,010Mar 06 07:20 PM
RUBINSTEIN JULIEPresident and COOMar 05 '25Sale6.9859,505415,540588,249Mar 06 07:19 PM
ROBINS HARLAN SChief Scientific OfficerMar 05 '25Sale6.9996,656675,2191,279,524Mar 06 07:18 PM
ROBINS CHAD MCEO and ChairmanMar 05 '25Sale6.98117,351819,4712,814,350Mar 06 07:17 PM
ROBINS CHAD MCEO and ChairmanMar 06 '25Sale7.64102,218780,9462,959,249Mar 06 07:17 PM
GRIFFIN MICHELLE RENEEDirectorMar 06 '25Sale7.9415,664124,37251,685Mar 06 07:14 PM
MICHELLE GRIFFINDirectorMar 06 '25Proposed Sale7.9415,664124,440Mar 06 04:10 PM
ROBINS CHAD MCEO and ChairmanFeb 19 '25Option Exercise6.32186,0801,176,0262,762,781Feb 21 07:28 PM
ROBINS CHAD MCEO and ChairmanFeb 20 '25Option Exercise6.3299,107626,3562,675,808Feb 21 07:28 PM
ROBINS CHAD MCEO and ChairmanFeb 19 '25Sale8.46186,0801,574,2372,576,701Feb 21 07:28 PM
ROBINS CHAD MCEO and ChairmanFeb 20 '25Sale8.4499,107836,4632,576,701Feb 21 07:28 PM
Chad RobinsOfficerFeb 20 '25Proposed Sale8.3799,107829,526Feb 20 04:02 PM
Chad RobinsOfficerFeb 19 '25Proposed Sale8.37186,0801,557,490Feb 19 04:51 PM
ROBINS CHAD MCEO and ChairmanFeb 18 '25Option Exercise6.32211,1601,334,5312,787,861Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 14 '25Option Exercise6.32158,9211,004,3812,735,622Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 13 '25Option Exercise6.32100,287633,8142,676,988Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 18 '25Sale8.50211,1601,794,8602,576,701Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 14 '25Sale8.46158,9211,344,4722,576,701Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 13 '25Sale8.44100,287846,4222,576,701Feb 18 08:21 PM
Chad RobinsOfficerFeb 18 '25Proposed Sale8.27211,1601,746,293Feb 18 05:35 PM
Chad RobinsOfficerFeb 14 '25Proposed Sale8.33158,9211,323,812Feb 14 04:11 PM
Chad RobinsOfficerFeb 13 '25Proposed Sale8.52100,287854,445Feb 13 05:11 PM
PISKEL KYLEChief Financial OfficerNov 18 '24Sale4.982481,235154,330Nov 19 06:45 PM
BOBULSKY SUSANChief Commercial Officer, MRDOct 08 '24Option Exercise1.985,0009,900253,290Oct 10 05:47 PM
Taylor Stacy LSVP and General CounselAug 22 '24Sale4.5026,922121,079139,365Aug 23 04:27 PM
STACY L TAYLOROfficerAug 22 '24Proposed Sale4.5026,922121,079Aug 22 04:18 PM